| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Sericoside targets inflammatory pathways, exerting its effects through its anti-inflammatory activity. It also acts on lipid metabolism, demonstrating strong lipolytic activity. The compound's mechanism of action involves modulating these pathways to reduce inflammation and promote the breakdown of lipids. Its ability to improve skin texture suggests it may also affect skin cell metabolism and extracellular matrix components. The precise molecular targets of sericoside are not fully detailed, but its triterpenoid structure is characteristic of compounds with diverse biological activities, including anti-inflammatory and anti-cancer effects.
|
|---|---|
| ln Vitro |
Sarcoside induces the dose- and time-dependent release of glycerol from deposited triglycerides into the cytoplasm of fully differentiated 3T3-L1 cells [2].
In vitro, sericoside has demonstrated anti-inflammatory activity. It has been shown to possess strong lipolytic activity, indicating its ability to stimulate the breakdown of lipids. These activities make it a valuable compound for studying inflammation and lipid metabolism in cell-based systems. Sericoside's potential neuroprotective and anti-cancer effects have also been noted, suggesting it may have multiple mechanisms of action. The compound is used in research to investigate these various biological activities and their underlying molecular mechanisms. |
| ln Vivo |
In vivo, sericoside has been studied for its effects on skin health, showing the ability to reduce skin wrinkles and improve skin texture. Its anti-inflammatory activity has also been observed in vivo, contributing to its potential therapeutic applications. The compound's lipolytic activity may have implications for metabolic health. While specific in vivo protocols are not detailed in the available literature, sericoside's biological activities suggest it has potential for treating inflammatory conditions and improving skin appearance. Further research is needed to fully characterize its in vivo pharmacology.
|
| Enzyme Assay |
In vitro assays for sericoside typically involve measuring its anti-inflammatory and lipolytic activities. For anti-inflammatory assays, cells (e.g., macrophages) are treated with sericoside and stimulated with an inflammatory agent such as lipopolysaccharide (LPS). The production of inflammatory mediators, such as nitric oxide (NO), prostaglandin E2 (PGE2), and pro-inflammatory cytokines (e.g., TNF-α, IL-6), is measured using Griess reagent, ELISA, or other appropriate methods. For lipolytic activity assays, adipocytes are treated with sericoside, and the release of free fatty acids and glycerol is measured as an indicator of lipolysis. The compound is typically dissolved in DMSO and diluted in cell culture medium for treatment.
|
| Cell Assay |
In vitro cell-based assays using sericoside are performed in various cell lines to study its biological activities. For anti-inflammatory studies, macrophages (e.g., RAW 264.7) or other immune cells are used. Cells are seeded in multi-well plates and treated with sericoside at concentrations ranging from 1-100 µM for 24-48 hours, with or without stimulation. Inflammatory marker production is measured by ELISA or other immunoassays. For lipolytic activity studies, adipocytes (e.g., 3T3-L1) are differentiated and treated with sericoside, and the release of free fatty acids and glycerol is measured. Cell viability is assessed to ensure the compound is not cytotoxic at the concentrations used.
|
| Animal Protocol |
Specific in vivo animal experiment protocols for sericoside are not detailed in the available literature. However, given its activities, potential studies could involve administering sericoside to animal models of inflammation or skin aging. The compound could be formulated for topical or oral administration. For skin studies, sericoside might be applied topically to the skin of mice to assess its effects on wrinkle formation and skin texture. For anti-inflammatory studies, it could be administered orally or intraperitoneally to models of acute or chronic inflammation. The route of administration, dosing, and duration would depend on the specific experimental design.
|
| ADME/Pharmacokinetics |
Sericoside has a molecular weight of approximately 666.84 g/mol and the formula C36H58O11. The compound is a solid and is stored as a powder at -20°C (up to 3 years) or 4°C (up to 2 years), protected from light. In solvent, it can be stored at -80°C for up to 6 months or at -20°C for up to 1 month. Its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion, have not been extensively characterized in the available literature. However, as a triterpenoid glycoside, it is likely to have moderate oral bioavailability and may be metabolized in the liver.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for sericoside are not provided in the available sources. As a naturally occurring compound with anti-inflammatory activity, it is likely to have a relatively low toxicity profile. However, as a research chemical, it is intended for laboratory use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling sericoside, including the use of appropriate personal protective equipment. Its purity is typically ≥98% or higher.
|
| References |
|
| Additional Infomation |
β-D-glucopyranosyl(2α,3β,4β,19α)-2,3,19,23-tetrahydroxyoleanolic-12-en-28-ester has been reported in Adinandra nitida, Rubus ellipticus var. obcordatus, and other organisms for which data are available. See also: Arjunglucoside I (note moved to).
Sericoside is a triterpenoid compound with anti-inflammatory activity, isolated from the Terminalia tree. It has the molecular formula C36H58O11 and a molecular weight of approximately 666.84 g/mol. Sericoside is known for its strong lipolytic activity and its ability to reduce skin wrinkles and improve skin texture. It is a glycoside of a triterpenoid, specifically a beta-D-glucopyranosyl ester. The compound is used in pharmacological research for its potential neuroprotective, anti-cancer, and anti-inflammatory effects. It is stored as a powder at -20°C or 4°C, protected from light, and is intended for research use only. |
| Molecular Formula |
C36H58O11
|
|---|---|
| Molecular Weight |
666.83912
|
| Exact Mass |
666.397
|
| CAS # |
55306-04-2
|
| PubChem CID |
76972524
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
775.0±60.0 °C at 760 mmHg
|
| Flash Point |
234.7±26.4 °C
|
| Vapour Pressure |
0.0±6.0 mmHg at 25°C
|
| Index of Refraction |
1.616
|
| LogP |
3.88
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
47
|
| Complexity |
1270
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4[C@@H](C(CC5)(C)C)O)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)(C[C@H]([C@@H]([C@]3(C)CO)O)O)C
|
| InChi Key |
CMZFNIMQBCBHEX-JRIAKSEUSA-N
|
| InChi Code |
InChI=1S/C36H58O11/c1-31(2)11-13-36(30(45)47-29-26(42)25(41)24(40)20(16-37)46-29)14-12-34(5)18(23(36)28(31)44)7-8-22-32(3)15-19(39)27(43)33(4,17-38)21(32)9-10-35(22,34)6/h7,19-29,37-44H,8-17H2,1-6H3/t19-,20-,21-,22-,23-,24-,25+,26-,27+,28+,29+,32+,33-,34-,35-,36+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1S,4aR,6aR,6aS,6bR,8aR,9S,10R,11R,12aR,14bS)-1,10,11-trihydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~149.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4996 mL | 7.4981 mL | 14.9961 mL | |
| 5 mM | 0.2999 mL | 1.4996 mL | 2.9992 mL | |
| 10 mM | 0.1500 mL | 0.7498 mL | 1.4996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
